Related Experiment Video
Updated: Jan 22, 2026

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
Published on: February 8, 2022
CAR-Expressing Natural Killer Cells for Cancer Retargeting
Stephan Kloess1,2, Anna Kretschmer1, Lilly Stahl1
1Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Abstract:
Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltrial.gov. In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an "off the shelf product" and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.
Related Concept Videos
Nature and Nurture
What is Natural Selection?
Cell Specific Gene Expression
Cell Specific Gene Expression
Chirality in Nature
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...

